Company: BGLC
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001477932-25-003821
Chunk: 30

Company: BioNexus Gene Lab Corp
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 30
---
24Table of Contents

BIONEXUS GENE LAB CORP. 

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS 

FOR THE THREE MONTHS ENDED MARCH 31, 2025 AND 2024 

(Currency expressed in United States Dollars (“US$”)) 

(Unaudited)

  Provision for genomic screening services  Trading of industrial chemicals  Investment holding  Total   Three months period ended March 2024              REVENUE $3,165  $2,378,686  $-  $2,381,851                  COST OF REVENUE  (2,252)  (2,014,568)  -   (2,016,820)                 GROSS PROFIT  913   364,118   -   365,031                  OTHER INCOME                Dividend income   -   8,946   -   8,946 Interest income  23,783   5,200   -   28,983 Fair value gain on investments in equity securities  -   84,785   -   84,785 Gain on disposal of investments in equity securities  -   6,181   -   6,181 Reversal of expected credit losses  -   31,752   -   31,752 Others  14,911   26,289   -   41,200 TOTAL OTHER INCOME  38,694   163,153   -   201,847                  OPERATING EXPENSES                Sales and marketing  (31,105)  (120,442)  (2,324)  (153,871)Research and development  (11,475)  -   -   (11,475)General and administrative  (38,275)  (130,421)  (147,098)  (315,794)Fair value loss on investments in equity securities  -   (44,297)  -   (44,297)Provision for expected credit losses   -   (120,469)  -   (